

# Vincenzo Di Nunno

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9308341/vincenzo-di-nunno-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

818  
citations

16  
h-index

23  
g-index

109  
ext. papers

1,162  
ext. citations

5.4  
avg, IF

4.61  
L-index

#	Paper	IF	Citations
85	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 852950	5.3	4
84	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , <b>2022</b> , 82, 491	12.1	2
83	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 1333-1353	3.5	4
82	PATH-15. NON-CANONICAL IDH 1 AND IDH 2 MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH GLIOMAS: RESULTS OF A META-ANALYSIS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi117-vi118	11.7	118
81	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , <b>2021</b> , 1	4.1	2
80	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , <b>2021</b> ,	3.8	2
79	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	2
78	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , <b>2021</b> , 13, 419-432	3.8	3
77	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , <b>2021</b> , 3008916211017213	1.7	0
76	IDH1 single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , <b>2021</b> , 221, 153445	3.4	2
75	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , <b>2021</b> , 221, 153447	3.4	1
74	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 457-473	4.5	3
73	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , <b>2021</b> , 26, 865-878	5.7	7
72	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , <b>2021</b> , 10, CNS72	4	6
71	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
70	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 32-40	3.3	12
69	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	6

68	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1581-1587	2.3	0
67	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , <b>2021</b> , 145, 171-178	7.5	3
66	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 757-773	3.2	0
65	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e04604	0.7	0
64	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , <b>2021</b> , 33,	2.4	1
63	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 1265-1272	3.5	1
62	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , <b>2020</b> , 16, 1053-1063	3.6	10
61	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1286	59.2	5
60	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 211-226	3.2	7
59	Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 707-707	2.2	1
58	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , <b>2020</b> , 11, 4582-4592	3.3	2
57	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 754-754	2.2	
56	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , <b>2020</b> , 21, 1463-1475	3.5	4
55	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , <b>2020</b> , 16, 1433-1439	3.6	8
54	MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2523-2523	2.2	
53	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 1047-1059	5.4	3
52	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 105-106	2.2	13
51	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , <b>2020</b> , 77, 761-763	10.2	18

50	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , <b>2020</b> , 15, FNL47	1.5	2
49	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 996	5.3	4
48	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 785-795	3.5	13
47	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>Lancet</i> 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. <i>European Urology Oncology</i> , <b>2020</b> , 3, 390	6.7	1
46	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e83-e90	3.3	10
45	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , <b>2020</b> , 87, 3-10	1.2	3
44	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 207-217	3.8	4
43	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 141-150	3.8	9
42	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
41	Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e339-e344	3.3	18
40	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , <b>2019</b> , 11,	6.6	21
39	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 631-643	3.8	21
38	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , <b>2019</b> , 39, 503-519	3.2	23
37	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	20
36	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1283-1289	3.8	12
35	BAP1 in solid tumors. <i>Future Oncology</i> , <b>2019</b> , 15, 2151-2162	3.6	17
34	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 142, 141-152	7	11
33	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e871-e877	3.3	18

32	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , <b>2019</b> , 23, 569-577	4.5	6
31	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <i>European Urology Oncology</i> , <b>2019</b> , 2, 603-604	6.7	1
30	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , <b>2019</b> , 11, 1507-1521	3.8	15
29	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 572-572	2.2	
28	Re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>N Engl J Med</i> 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?. <i>European Urology Oncology</i> , <b>2019</b> , 2, 340-341	6.7	3
27	New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?. <i>European Urology Oncology</i> , <b>2019</b> , 2, 471	6.7	2
26	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , <b>2019</b> , 17, 917-927	2.5	2
25	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , <b>2019</b> , 15, 563-565	3.6	1
24	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , <b>2019</b> , 8,	7.9	20
23	CheckMate 214 patient-reported outcomes: listening to our patients. <i>Lancet Oncology</i> , <b>2019</b> , 20, 179-180	21.7	2
22	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , <b>2018</b> , 10, 65-77	3.2	14
21	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 64, 11-20	14.4	57
20	Atezolizumab for platinum-treated metastatic urothelial carcinoma. <i>Lancet, The</i> , <b>2018</b> , 391, 716-718	40	9
19	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. <i>Lancet Oncol</i> 2018;19:405-15. <i>European Urology</i> , <b>2018</b> , 1, 102-103	10.2	0
18	Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. <i>Eur Urol</i> 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? <i>European Urology</i> , <b>2018</b> , 74, e118-e119	10.2	2
17	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 129, 124-132	7	11
16	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 2559-2564	3.6	5
15	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 710-715	2.4	5

14	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 80-85	14.4	18
13	Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-8. <i>European Urology</i> , <b>2018</b> , 73, e72	10.2	1
12	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 397	5.3	15
11	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , <b>2018</b> , 13, 705-714	5	24
10	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 911-913	2.4	2
9	Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e437	21.7	
8	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>Eur Urol</i> 2018;73:462-8. <i>European Urology</i> , <b>2018</b> , 74, e12-e13	10.2	
7	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1021-1025	10.25	13
6	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 68-73	14.4	52
5	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 60, 152-157	14.4	25
4	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. <i>Tumori</i> , <b>2017</b> , 103, 405-421	1.7	31
3	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2017</b> , 2, 169-175	1.6	8
2	The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2016</b> , 1, 369-377	1.6	2
1	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 353-63	2.4	4